Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has now selected an initial 13 sites in Turkey for its US FDA Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19).
The company, in collaboration with Delta Health, has recently received approval for the trial by the Ethics Committee of Istinye University in Turkey and is working with the university and MLP Care, the largest hospital group in Turkey. It has access to 30 clinical research sites and over 6,000 in-patient hospital beds.
"Our expansion to Turkey is important to our enrollment goals and commercialization initiatives in the U.S. and international markets," said Michael Frank, CEO of Revive Therapeutics in a statement.
READ: Revive Therapeutics says it is on track with Phase 3 clinical trial for Bucillamine in COVID-19
The following sites in Turkey have been selected:
- Istinye University Faculty of Medicine
- Liv Hospital Vadi UNKNOWN(304)stanbul
- VM Medical Park Samsun Hospital
- Liv Hospital Samsun
- Medical Park Ankara Hospital
- VM Medical Park Maltepe Hospital
- Istinye University Research Hospital
- Medical Park Goztepe Hospital Complex
- Aydin University Research Hospital
- VM Medical Park Pendik Hospital
- Medical Park Bahcelievler Hospital
- VM Medical Park Mersin Hospital
- Medical Park Antalya Hospital Complex
In Turkey, coronavirus (Covid-19) infections continue to grow. Turkey has recorded 12.8 million infections and about 90,000 deaths.
Revive is evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. It has noted that it is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Overall, the company is focused on the research and development of therapeutics for infectious diseases and rare disorders, and aims to take advantage of several regulatory incentives awarded by the US Food & Drug Administration (FDA) such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations.
Contact the writer at giles@proactiveinvestors.com